7.70
0.17 (2.26%)
| Previous Close | 7.53 |
| Open | 7.58 |
| Volume | 5,359 |
| Avg. Volume (3M) | 16,581 |
| Market Cap | 8,309,686 |
| Price / Sales | 58.26 |
| Price / Book | 0.920 |
| 52 Weeks Range | |
| Earnings Date | 24 Mar 2025 |
| Profit Margin | 3,521.74% |
| Operating Margin (TTM) | -853.23% |
| Diluted EPS (TTM) | -7.46 |
| Quarterly Revenue Growth (YOY) | -69.80% |
| Total Debt/Equity (MRQ) | 0.49% |
| Current Ratio (MRQ) | 3.03 |
| Operating Cash Flow (TTM) | -3.78 M |
| Levered Free Cash Flow (TTM) | -3.57 M |
| Return on Assets (TTM) | -25.09% |
| Return on Equity (TTM) | -163.15% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Addex Therapeutics Ltd | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 1.0 |
| Average | 0.50 |
|
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Institutions | 1.13% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |